Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Labriola, Matthew
Zhu, Jason
Gupta, Rajan
McCall, Shannon
Jackson, Jennifer
White, James R.
Weingartner, Elizabeth
Kong, Eric
Simone, Peter
Papp, Eniko
Gerding, Kelly
Simmons, John
George, Daniel J.
Zhang, Tian
机构：
[1] Duke Med Ctr, Durham, NC USA
[2] Duke Univ, Durham, NC USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Personal Genome Diagnost Inc, Baltimore, MD USA
[5] Duke Canc Inst, Durham, NC USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.400
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
400
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC).
    Talukder, Rafee
    Bakaloudi, Dimitra Rafailia
    Makrakis, Dimitrios
    Tripathi, Nishita
    Agarwal, Neeraj
    Jindal, Tanya
    Koshkin, Vadim S.
    Johnson, Jeffrey
    Zakharia, Yousef
    Brown, Jason
    Rey-Cardenas, Macarena
    Castellano, Daniel
    Alva, Ajjai Shivaram
    Zakopoulou, Roubini
    Korolewicz, James
    Drakaki, Alexandra
    Barata, Pedro C.
    Grivas, Petros
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
    Knepper, Todd C.
    Montesion, Meagan
    Russell, Jeffery S.
    Sokol, Ethan S.
    Frampton, Garrett M.
    Miller, Vincent A.
    Albacker, Lee A.
    McLeod, Howard L.
    Eroglu, Zeynep
    Khushalani, Nikhil, I
    Sondak, Vernon K.
    Messina, Jane L.
    Schell, Michael J.
    DeCaprio, James A.
    Tsai, Kenneth Y.
    Brohl, Andrew S.
    CLINICAL CANCER RESEARCH, 2019, 25 (19) : 5961 - 5971
  • [23] Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC)
    Morales-Barrera, Rafael
    Vidal Casinello, Natalia
    Bonfill, Teresa
    Domenech, Montserrat
    Suarez Rodriguez, Cristina
    Puente, Javier
    Giner Joaquin, Julia
    Figols, Mariona
    Galante, Isabel
    Carrion, Albert
    Lopez, Hector
    Gonzalez, Macarena
    Roche, Sarai
    Mateo, Joaquin
    Gallardo Diaz, Enrique
    Fernandez Saez, Carlos
    Valverde Morales, Claudia Maria
    de Torres, Ines
    Morote, Juan
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Adoption of immune checkpoint inhibitors (ICI) for unresectable locally advanced or metastatic urothelial carcinoma (u/mUC): A retrospective assessment of community oncology practices
    Aguilar, Kathleen M.
    Grivas, Petros
    Seal, Brian S.
    Robert, Nicholas J.
    Davies, Kalatu
    Fleming, Mark T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [25] Decrease in derived neutrophil-to-lymphocyte ratio (dNLR) related to immune checkpoint inhibitors (ICI) benefit in patients with metastatic urothelial carcinoma (mUC)
    Oberoi, H. K.
    Ghiglione, L.
    Gorria Puga, T.
    Fernandez Manas, L.
    Ferrer Mileo, L.
    Orrillo Sarmiento, M.
    Prat, A.
    Reig Torras, O.
    Mellado, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S596 - S597
  • [26] The effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitor (ICI) efficacy in patients with metastatic urothelial carcinoma (mUC) in real-world setting.
    Gupta, Shilpa
    Khan, Mohammad Siddique
    Radakovich, Nathan
    Wei, Wei
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Mian, Omar Y.
    Dawsey, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Alice Tzeng
    C. Marcela Diaz-Montero
    Patricia A. Rayman
    Jin S. Kim
    Paul G. Pavicic
    James H. Finke
    Pedro C. Barata
    Marcelo Lamenza
    Sarah Devonshire
    Kim Schach
    Hamid Emamekhoo
    Marc S. Ernstoff
    Christopher J. Hoimes
    Brian I. Rini
    Jorge A. Garcia
    Timothy D. Gilligan
    Moshe C. Ornstein
    Petros Grivas
    Targeted Oncology, 2018, 13 : 599 - 609
  • [28] Immune checkpoint inhibition in metastatic urothelial carcinoma
    Bedke, Jens
    Todenhoefer, Tilman
    Stenzl, Arnulf
    AKTUELLE UROLOGIE, 2018, 49 (02) : 178 - 186
  • [29] Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin S.
    Pavicic, Paul G., Jr.
    Finke, James H.
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe C.
    Grivas, Petros
    TARGETED ONCOLOGY, 2018, 13 (05) : 599 - 609
  • [30] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
    Brown, Landon C.
    Zhu, Jason
    Desai, Kunal
    Kinsey, Emily
    Kao, Chester
    Lee, Yong Hee
    Pabla, Sarabjot
    Labriola, Matthew K.
    Tran, Jennifer
    Dragnev, Konstantin H.
    Tafe, Laura J.
    Dayyani, Farshid
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Glenn, Sean T.
    Nesline, Mary K.
    George, Saby
    Zibelman, Matthew
    Morrison, Carl
    Ornstein, Moshe C.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
12345